Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Algernon Pharmaceuticals Inc (OP: AGNPF ) 0.0901 +0.0101 (+12.62%) Streaming Delayed Price Updated: 10:10 AM EDT, Jul 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Algernon Pharmaceuticals Inc < Previous 1 2 Next > Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design April 03, 2024 Via Benzinga Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More August 14, 2023 First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published Via Benzinga DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study August 08, 2023 Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) (CSE:AGN) (FRANKFURT:AGW0), has completed a feasibility study and has finalized its clinical trial design... Via Benzinga Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study July 18, 2022 Via Benzinga DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up June 05, 2023 Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous... Via Benzinga How To Finance A Psychedelics Business? Learn From These Four Companies April 04, 2023 Clearmind Medicine Announces Pricing of $3.5 Million Public Offering Via Benzinga Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment April 04, 2023 Canadian biopharma company Algernon Pharmaceuticals Inc. Via Benzinga Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More March 07, 2023 Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... Via Benzinga Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI March 03, 2023 In this new podcast, TDR Founder Shadd Dales interviewed Algernon Pharmaceuticals (OTC: AGNPF) CEO, Christopher Moreau. Via Benzinga Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program March 01, 2023 Canadian clinical-stage psychedelics developer Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) will start trading its Class A common shares following a 4-to-1 stock split towards increasing liquidity. Via Benzinga Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More February 27, 2023 Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... Via Benzinga Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More February 21, 2023 Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... Via Benzinga Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program February 21, 2023 Biopharma company Algernon Pharmaceuticals (OTCQB: AGNPF) has launched a new clinical research program via a subsidiary. Via Benzinga Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose February 16, 2023 Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of Via Benzinga A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing January 18, 2023 Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed Via Benzinga Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One January 03, 2023 The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs. Via Benzinga EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans December 15, 2022 Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Via Benzinga Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More November 21, 2022 Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy Via Benzinga Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon November 16, 2022 Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. Via Benzinga Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video November 08, 2022 Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) – The company is focused on... Via Newsfile Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University October 24, 2022 Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc. Via Benzinga A Foundational Study On Stroke Is Ready. Here Is Why It's Important September 12, 2022 Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for huma Via Benzinga Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment September 08, 2022 Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin... Via Benzinga Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution August 23, 2022 Biotech clinical-stage company Algernon Pharmaceuticals Inc. Via Benzinga The Power Play by The Market Herald Releases New Interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals Discussing Their Latest News November 01, 2021 VANCOUVER, BC / ACCESSWIRE / November 1, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza... From The Market Herald Via AccessWire The Power Play by The Market Herald Announces Interviews with Algernon Pharmaceuticals, NextechAR, UCore Rare Metals, Falcon Gold, and Durango Resources on Latest Company News October 15, 2021 VANCOUVER, BC / ACCESSWIRE / October 15, 2021 / The Market Herald, the leading source of authoritative breaking stock market news for self-directed investors spoke with Algernon Pharmaceuticals, UCore... From The Market Herald Via AccessWire Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation October 18, 2021 The Week In Psychedelics Via Benzinga Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics September 13, 2021 Last Week In Psychedelics: Via Benzinga There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are October 13, 2021 Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... Via Benzinga < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
